Global Targeted Drugs for Neurodegenerative Diseases Market Research Report 2025(Status and Outlook)

Report Overview

Targeted drugs for neurodegenerative diseases represent a specialized class of pharmaceuticals designed to address the underlying mechanisms of disorders such as Alzheimer's, Parkinson's, Huntington's, and amyotrophic lateral sclerosis (ALS). Unlike traditional treatments that focus on symptom management, these drugs aim to modify disease progression by targeting specific pathological pathways, such as protein misfolding (e.g., beta-amyloid or tau in Alzheimer's), neuroinflammation, or genetic mutations (e.g., huntingtin protein in Huntington's). The market for these drugs is driven by increasing global prevalence of neurodegenerative conditions due to aging populations, advancements in biomarker research enabling early diagnosis, and significant investments in precision medicine and biologics. However, challenges include high development costs, regulatory hurdles, and the complexity of crossing the blood-brain barrier. Key players in this space include Biogen, Roche, Novartis, and smaller biotech firms specializing in gene therapies or monoclonal antibodies, with growth further fueled by rising demand for disease-modifying therapies and breakthroughs in CRISPR and RNA-targeting technologies.

The global Targeted Drugs for Neurodegenerative Diseases market size was estimated at USD 2690.17 million in 2024, exhibiting a CAGR of 8.42% during the forecast period.

This report provides a deep insight into the global Targeted Drugs for Neurodegenerative Diseases market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, SWOT analysis, value chain analysis, etc.

The analysis helps the reader to shape the competition within the industries and strategies for the competitive environment to enhance the potential profit. Furthermore, it provides a simple framework for evaluating and accessing the position of the business organization. The report structure also focuses on the competitive landscape of the Global Targeted Drugs for Neurodegenerative Diseases Market, this report introduces in detail the market share, market performance, product situation, operation situation, etc. of the main players, which helps the readers in the industry to identify the main competitors and deeply understand the competition pattern of the market.

In a word, this report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the Targeted Drugs for Neurodegenerative Diseases market in any manner.

Global Targeted Drugs for Neurodegenerative Diseases Market: Market Segmentation Analysis

The research report includes specific segments by region (country), manufacturers, Type, and Application. Market segmentation creates subsets of a market based on product type, end-user or application, Geographic, and other factors. By understanding the market segments, the decision-maker can leverage this targeting in the product, sales, and marketing strategies. Market segments can power your product development cycles by informing how you create product offerings for different segments.

Key Company

Acadia Pharmaceuticals Inc.

Kyowa Kirin

Supernus Pharmaceuticals

UCB

Sumitomo Pharma

Biogen

Eisai Inc.

Eli Lilly

Green Valley

NOVARTIS

Bristol-Myers Squibb

Janssen

Sanofi

Roche

Neurocrine

Lundbeck

Teva

Market Segmentation (by Type)

Injection

Oral

Market Segmentation (by Application)

Parkinson's Disease (PD)

Alzheimer's Disease (AD)

Huntington's Disease (HD)

Tardive Dyskinesia (TD)

Multiple Sclerosis (MS)

Geographic Segmentation

North America (USA, Canada, Mexico)

Europe (Germany, UK, France, Russia, Italy, Rest of Europe)

Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)

South America (Brazil, Argentina, Columbia, Rest of South America)

The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)

Key Benefits of This Market Research:

Industry drivers, restraints, and opportunities covered in the study

Neutral perspective on the market performance

Recent industry trends and developments

Competitive landscape & strategies of key players

Potential & niche segments and regions exhibiting promising growth covered

Historical, current, and projected market size, in terms of value

In-depth analysis of the Targeted Drugs for Neurodegenerative Diseases Market

Overview of the regional outlook of the Targeted Drugs for Neurodegenerative Diseases Market:

Chapter Outline

Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.

Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the Targeted Drugs for Neurodegenerative Diseases Market and its likely evolution in the short to mid-term, and long term.

Chapter 3 makes a detailed analysis of the market's competitive landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.

Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.

Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 8 provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 9 shares the main producing countries of Targeted Drugs for Neurodegenerative Diseases, their output value, profit level, regional supply, production capacity layout, etc. from the supply side.

Chapter 10 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.

Chapter 11 provides a quantitative analysis of the market size and development potential of each region in the next five years.

Chapter 12 provides a quantitative analysis of the market size and development potential of each market segment in the next five years.

Chapter 13 is the main points and conclusions of the report.

Key Reasons to Buy this Report:

Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change

This enables you to anticipate market changes to remain ahead of your competitors

You will be able to copy data from the Excel spreadsheet straight into your marketing plans, business presentations, or other strategic documents

The concise analysis, clear graph, and table format will enable you to pinpoint the information you require quickly

Provision of market value data for each segment and sub-segment

Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market

Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region

Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled

Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players

The current as well as the future market outlook of the industry concerning recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions

Includes in-depth analysis of the market from various perspectives through Porter’s five forces analysis

Provides insight into the market through Value Chain

Market dynamics scenario, along with growth opportunities of the market in the years to come


1 Research Methodology and Statistical Scope
1.1 Market Definition and Statistical Scope of Targeted Drugs for Neurodegenerative Diseases
1.2 Key Market Segments
1.2.1 Targeted Drugs for Neurodegenerative Diseases Segment by Type
1.2.2 Targeted Drugs for Neurodegenerative Diseases Segment by Application
1.3 Methodology & Sources of Information
1.3.1 Research Methodology
1.3.2 Research Process
1.3.3 Market Breakdown and Data Triangulation
1.3.4 Base Year
1.3.5 Report Assumptions & Caveats
2 Targeted Drugs for Neurodegenerative Diseases Market Overview
2.1 Global Market Overview
2.1.1 Global Targeted Drugs for Neurodegenerative Diseases Market Size (M USD) Estimates and Forecasts (2020-2033)
2.1.2 Global Targeted Drugs for Neurodegenerative Diseases Sales Estimates and Forecasts (2020-2033)
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region
3 Targeted Drugs for Neurodegenerative Diseases Market Competitive Landscape
3.1 Company Assessment Quadrant
3.2 Global Targeted Drugs for Neurodegenerative Diseases Product Life Cycle
3.3 Global Targeted Drugs for Neurodegenerative Diseases Sales by Manufacturers (2020-2025)
3.4 Global Targeted Drugs for Neurodegenerative Diseases Revenue Market Share by Manufacturers (2020-2025)
3.5 Targeted Drugs for Neurodegenerative Diseases Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Targeted Drugs for Neurodegenerative Diseases Average Price by Manufacturers (2020-2025)
3.7 Manufacturers’ Manufacturing Sites, Areas Served, and Product Types
3.8 Targeted Drugs for Neurodegenerative Diseases Market Competitive Situation and Trends
3.8.1 Targeted Drugs for Neurodegenerative Diseases Market Concentration Rate
3.8.2 Global 5 and 10 Largest Targeted Drugs for Neurodegenerative Diseases Players Market Share by Revenue
3.8.3 Mergers & Acquisitions, Expansion
4 Targeted Drugs for Neurodegenerative Diseases Industry Chain Analysis
4.1 Targeted Drugs for Neurodegenerative Diseases Industry Chain Analysis
4.2 Market Overview of Key Raw Materials
4.3 Midstream Market Analysis
4.4 Downstream Customer Analysis
5 The Development and Dynamics of Targeted Drugs for Neurodegenerative Diseases Market
5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Industry News
5.4.1 New Product Developments
5.4.2 Mergers & Acquisitions
5.4.3 Expansions
5.4.4 Collaboration/Supply Contracts
5.5 PEST Analysis
5.5.1 Industry Policies Analysis
5.5.2 Economic Environment Analysis
5.5.3 Social Environment Analysis
5.5.4 Technological Environment Analysis
5.6 Global Targeted Drugs for Neurodegenerative Diseases Market Porter's Five Forces Analysis
5.6.1 Global Trade Frictions
5.6.2 U.S. Tariff Policy – April 2025
5.6.3 Global Trade Frictions and Their Impacts to Targeted Drugs for Neurodegenerative Diseases Market
5.7 ESG Ratings of Leading Companies
6 Targeted Drugs for Neurodegenerative Diseases Market Segmentation by Type
6.1 Evaluation Matrix of Segment Market Development Potential (Type)
6.2 Global Targeted Drugs for Neurodegenerative Diseases Sales Market Share by Type (2020-2025)
6.3 Global Targeted Drugs for Neurodegenerative Diseases Market Size Market Share by Type (2020-2025)
6.4 Global Targeted Drugs for Neurodegenerative Diseases Price by Type (2020-2025)
7 Targeted Drugs for Neurodegenerative Diseases Market Segmentation by Application
7.1 Evaluation Matrix of Segment Market Development Potential (Application)
7.2 Global Targeted Drugs for Neurodegenerative Diseases Market Sales by Application (2020-2025)
7.3 Global Targeted Drugs for Neurodegenerative Diseases Market Size (M USD) by Application (2020-2025)
7.4 Global Targeted Drugs for Neurodegenerative Diseases Sales Growth Rate by Application (2020-2025)
8 Targeted Drugs for Neurodegenerative Diseases Market Sales by Region
8.1 Global Targeted Drugs for Neurodegenerative Diseases Sales by Region
8.1.1 Global Targeted Drugs for Neurodegenerative Diseases Sales by Region
8.1.2 Global Targeted Drugs for Neurodegenerative Diseases Sales Market Share by Region
8.2 Global Targeted Drugs for Neurodegenerative Diseases Market Size by Region
8.2.1 Global Targeted Drugs for Neurodegenerative Diseases Market Size by Region
8.2.2 Global Targeted Drugs for Neurodegenerative Diseases Market Size Market Share by Region
8.3 North America
8.3.1 North America Targeted Drugs for Neurodegenerative Diseases Sales by Country
8.3.2 North America Targeted Drugs for Neurodegenerative Diseases Market Size by Country
8.3.3 U.S. Market Overview
8.3.4 Canada Market Overview
8.3.5 Mexico Market Overview
8.4 Europe
8.4.1 Europe Targeted Drugs for Neurodegenerative Diseases Sales by Country
8.4.2 Europe Targeted Drugs for Neurodegenerative Diseases Market Size by Country
8.4.3 Germany Market Overview
8.4.4 France Market Overview
8.4.5 U.K. Market Overview
8.4.6 Italy Market Overview
8.4.7 Spain Market Overview
8.5 Asia Pacific
8.5.1 Asia Pacific Targeted Drugs for Neurodegenerative Diseases Sales by Region
8.5.2 Asia Pacific Targeted Drugs for Neurodegenerative Diseases Market Size by Region
8.5.3 China Market Overview
8.5.4 Japan Market Overview
8.5.5 South Korea Market Overview
8.5.6 India Market Overview
8.5.7 Southeast Asia Market Overview
8.6 South America
8.6.1 South America Targeted Drugs for Neurodegenerative Diseases Sales by Country
8.6.2 South America Targeted Drugs for Neurodegenerative Diseases Market Size by Country
8.6.3 Brazil Market Overview
8.6.4 Argentina Market Overview
8.6.5 Columbia Market Overview
8.7 Middle East and Africa
8.7.1 Middle East and Africa Targeted Drugs for Neurodegenerative Diseases Sales by Region
8.7.2 Middle East and Africa Targeted Drugs for Neurodegenerative Diseases Market Size by Region
8.7.3 Saudi Arabia Market Overview
8.7.4 UAE Market Overview
8.7.5 Egypt Market Overview
8.7.6 Nigeria Market Overview
8.7.7 South Africa Market Overview
9 Targeted Drugs for Neurodegenerative Diseases Market Production by Region
9.1 Global Production of Targeted Drugs for Neurodegenerative Diseases by Region(2020-2025)
9.2 Global Targeted Drugs for Neurodegenerative Diseases Revenue Market Share by Region (2020-2025)
9.3 Global Targeted Drugs for Neurodegenerative Diseases Production, Revenue, Price and Gross Margin (2020-2025)
9.4 North America Targeted Drugs for Neurodegenerative Diseases Production
9.4.1 North America Targeted Drugs for Neurodegenerative Diseases Production Growth Rate (2020-2025)
9.4.2 North America Targeted Drugs for Neurodegenerative Diseases Production, Revenue, Price and Gross Margin (2020-2025)
9.5 Europe Targeted Drugs for Neurodegenerative Diseases Production
9.5.1 Europe Targeted Drugs for Neurodegenerative Diseases Production Growth Rate (2020-2025)
9.5.2 Europe Targeted Drugs for Neurodegenerative Diseases Production, Revenue, Price and Gross Margin (2020-2025)
9.6 Japan Targeted Drugs for Neurodegenerative Diseases Production (2020-2025)
9.6.1 Japan Targeted Drugs for Neurodegenerative Diseases Production Growth Rate (2020-2025)
9.6.2 Japan Targeted Drugs for Neurodegenerative Diseases Production, Revenue, Price and Gross Margin (2020-2025)
9.7 China Targeted Drugs for Neurodegenerative Diseases Production (2020-2025)
9.7.1 China Targeted Drugs for Neurodegenerative Diseases Production Growth Rate (2020-2025)
9.7.2 China Targeted Drugs for Neurodegenerative Diseases Production, Revenue, Price and Gross Margin (2020-2025)
10 Key Companies Profile
10.1 Acadia Pharmaceuticals Inc.
10.1.1 Acadia Pharmaceuticals Inc. Basic Information
10.1.2 Acadia Pharmaceuticals Inc. Targeted Drugs for Neurodegenerative Diseases Product Overview
10.1.3 Acadia Pharmaceuticals Inc. Targeted Drugs for Neurodegenerative Diseases Product Market Performance
10.1.4 Acadia Pharmaceuticals Inc. Business Overview
10.1.5 Acadia Pharmaceuticals Inc. SWOT Analysis
10.1.6 Acadia Pharmaceuticals Inc. Recent Developments
10.2 Kyowa Kirin
10.2.1 Kyowa Kirin Basic Information
10.2.2 Kyowa Kirin Targeted Drugs for Neurodegenerative Diseases Product Overview
10.2.3 Kyowa Kirin Targeted Drugs for Neurodegenerative Diseases Product Market Performance
10.2.4 Kyowa Kirin Business Overview
10.2.5 Kyowa Kirin SWOT Analysis
10.2.6 Kyowa Kirin Recent Developments
10.3 Supernus Pharmaceuticals
10.3.1 Supernus Pharmaceuticals Basic Information
10.3.2 Supernus Pharmaceuticals Targeted Drugs for Neurodegenerative Diseases Product Overview
10.3.3 Supernus Pharmaceuticals Targeted Drugs for Neurodegenerative Diseases Product Market Performance
10.3.4 Supernus Pharmaceuticals Business Overview
10.3.5 Supernus Pharmaceuticals SWOT Analysis
10.3.6 Supernus Pharmaceuticals Recent Developments
10.4 UCB
10.4.1 UCB Basic Information
10.4.2 UCB Targeted Drugs for Neurodegenerative Diseases Product Overview
10.4.3 UCB Targeted Drugs for Neurodegenerative Diseases Product Market Performance
10.4.4 UCB Business Overview
10.4.5 UCB Recent Developments
10.5 Sumitomo Pharma
10.5.1 Sumitomo Pharma Basic Information
10.5.2 Sumitomo Pharma Targeted Drugs for Neurodegenerative Diseases Product Overview
10.5.3 Sumitomo Pharma Targeted Drugs for Neurodegenerative Diseases Product Market Performance
10.5.4 Sumitomo Pharma Business Overview
10.5.5 Sumitomo Pharma Recent Developments
10.6 Biogen
10.6.1 Biogen Basic Information
10.6.2 Biogen Targeted Drugs for Neurodegenerative Diseases Product Overview
10.6.3 Biogen Targeted Drugs for Neurodegenerative Diseases Product Market Performance
10.6.4 Biogen Business Overview
10.6.5 Biogen Recent Developments
10.7 Eisai Inc.
10.7.1 Eisai Inc. Basic Information
10.7.2 Eisai Inc. Targeted Drugs for Neurodegenerative Diseases Product Overview
10.7.3 Eisai Inc. Targeted Drugs for Neurodegenerative Diseases Product Market Performance
10.7.4 Eisai Inc. Business Overview
10.7.5 Eisai Inc. Recent Developments
10.8 Eli Lilly
10.8.1 Eli Lilly Basic Information
10.8.2 Eli Lilly Targeted Drugs for Neurodegenerative Diseases Product Overview
10.8.3 Eli Lilly Targeted Drugs for Neurodegenerative Diseases Product Market Performance
10.8.4 Eli Lilly Business Overview
10.8.5 Eli Lilly Recent Developments
10.9 Green Valley
10.9.1 Green Valley Basic Information
10.9.2 Green Valley Targeted Drugs for Neurodegenerative Diseases Product Overview
10.9.3 Green Valley Targeted Drugs for Neurodegenerative Diseases Product Market Performance
10.9.4 Green Valley Business Overview
10.9.5 Green Valley Recent Developments
10.10 NOVARTIS
10.10.1 NOVARTIS Basic Information
10.10.2 NOVARTIS Targeted Drugs for Neurodegenerative Diseases Product Overview
10.10.3 NOVARTIS Targeted Drugs for Neurodegenerative Diseases Product Market Performance
10.10.4 NOVARTIS Business Overview
10.10.5 NOVARTIS Recent Developments
10.11 Bristol-Myers Squibb
10.11.1 Bristol-Myers Squibb Basic Information
10.11.2 Bristol-Myers Squibb Targeted Drugs for Neurodegenerative Diseases Product Overview
10.11.3 Bristol-Myers Squibb Targeted Drugs for Neurodegenerative Diseases Product Market Performance
10.11.4 Bristol-Myers Squibb Business Overview
10.11.5 Bristol-Myers Squibb Recent Developments
10.12 Janssen
10.12.1 Janssen Basic Information
10.12.2 Janssen Targeted Drugs for Neurodegenerative Diseases Product Overview
10.12.3 Janssen Targeted Drugs for Neurodegenerative Diseases Product Market Performance
10.12.4 Janssen Business Overview
10.12.5 Janssen Recent Developments
10.13 Sanofi
10.13.1 Sanofi Basic Information
10.13.2 Sanofi Targeted Drugs for Neurodegenerative Diseases Product Overview
10.13.3 Sanofi Targeted Drugs for Neurodegenerative Diseases Product Market Performance
10.13.4 Sanofi Business Overview
10.13.5 Sanofi Recent Developments
10.14 Roche
10.14.1 Roche Basic Information
10.14.2 Roche Targeted Drugs for Neurodegenerative Diseases Product Overview
10.14.3 Roche Targeted Drugs for Neurodegenerative Diseases Product Market Performance
10.14.4 Roche Business Overview
10.14.5 Roche Recent Developments
10.15 Neurocrine
10.15.1 Neurocrine Basic Information
10.15.2 Neurocrine Targeted Drugs for Neurodegenerative Diseases Product Overview
10.15.3 Neurocrine Targeted Drugs for Neurodegenerative Diseases Product Market Performance
10.15.4 Neurocrine Business Overview
10.15.5 Neurocrine Recent Developments
10.16 Lundbeck
10.16.1 Lundbeck Basic Information
10.16.2 Lundbeck Targeted Drugs for Neurodegenerative Diseases Product Overview
10.16.3 Lundbeck Targeted Drugs for Neurodegenerative Diseases Product Market Performance
10.16.4 Lundbeck Business Overview
10.16.5 Lundbeck Recent Developments
10.17 Teva
10.17.1 Teva Basic Information
10.17.2 Teva Targeted Drugs for Neurodegenerative Diseases Product Overview
10.17.3 Teva Targeted Drugs for Neurodegenerative Diseases Product Market Performance
10.17.4 Teva Business Overview
10.17.5 Teva Recent Developments
11 Targeted Drugs for Neurodegenerative Diseases Market Forecast by Region
11.1 Global Targeted Drugs for Neurodegenerative Diseases Market Size Forecast
11.2 Global Targeted Drugs for Neurodegenerative Diseases Market Forecast by Region
11.2.1 North America Market Size Forecast by Country
11.2.2 Europe Targeted Drugs for Neurodegenerative Diseases Market Size Forecast by Country
11.2.3 Asia Pacific Targeted Drugs for Neurodegenerative Diseases Market Size Forecast by Region
11.2.4 South America Targeted Drugs for Neurodegenerative Diseases Market Size Forecast by Country
11.2.5 Middle East and Africa Forecasted Sales of Targeted Drugs for Neurodegenerative Diseases by Country
12 Forecast Market by Type and by Application (2026-2033)
12.1 Global Targeted Drugs for Neurodegenerative Diseases Market Forecast by Type (2026-2033)
12.1.1 Global Forecasted Sales of Targeted Drugs for Neurodegenerative Diseases by Type (2026-2033)
12.1.2 Global Targeted Drugs for Neurodegenerative Diseases Market Size Forecast by Type (2026-2033)
12.1.3 Global Forecasted Price of Targeted Drugs for Neurodegenerative Diseases by Type (2026-2033)
12.2 Global Targeted Drugs for Neurodegenerative Diseases Market Forecast by Application (2026-2033)
12.2.1 Global Targeted Drugs for Neurodegenerative Diseases Sales (K Units) Forecast by Application
12.2.2 Global Targeted Drugs for Neurodegenerative Diseases Market Size (M USD) Forecast by Application (2026-2033)
13 Conclusion and Key Findings

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings